Cutaneous Leukocytoclastic Vasculitis as a rare adverse event of infliximab in Crohn’s disease: a case report

Abstract Leukocytoclastic vasculitis (LCV) is a rare, immune-mediated small-vessel vasculitis that can be triggered by infections, autoimmune diseases, or medications, including biologic therapies. We present a case of a patient with Crohn’s disease who developed biopsy proven LCV during longterm infliximab therapy. After four years of sustained remission on infliximab, she developed cutaneous palpable purpura affecting the lower extremities. Laboratory evaluation excluded systemic vasculitis, infection, and other secondary causes. Histopathology confirmed leukocytoclastic vasculitis. Discontinuation of infliximab, led to complete resolution of skin lesions. This case underscores the importance of clinician awareness of rare biologic-associated adverse effects and highlights the need for timely recognition and management to prevent systemic involvement.